CureVac and Acuitas wind up COVID-19 vaccine dispute
Settlement comes after Acuitas alleged CureVac deliberately omitted its scientists as inventors on four US patents related to COVID-19 vaccines, claiming co-inventorship | Patents in suit relate to ongoing litigation with Pfizer and BioNTech.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
21 December 2023 CureVac suffers a blow following a favourable earlier opinion delivered by the German Federal Patent Court | Decision invalidates a patent related to mRNA tech.
6 September 2022 CureVac accuses Pfizer and its German partner of infringing patented tech in landmark COVID-19 treatment | The pharma giant says that the patents are invalid